Physician profile
Nahid D Elyas
NPI 1134170384
$2,429.58
in general payments reported to CMS, 2019-2025
20 companies · $671 in 2025
The $671 reported for 2025 was more than what 81% of Adolescent Medicine (Internal Medicine) providers received nationally (typical 2025 total: $165).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2021: $133 · 2022: $104 · 2023: $604 · 2024: $234 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,508.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $347.76 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $340.89 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $233.98 | 2019-2023 | Veozah |
| Merck Sharp & Dohme LLC | $209.28 | 2019-2021 | |
| Exact Sciences Corporation | $169.48 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $139.90 | 2024-2025 | Breztri, Airsupra |
| Abbott Laboratories | $139.77 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Actelion Pharmaceuticals US, INC. | $126.00 | 2023 | Opsumit, Uptravi |
| Medtronic, INC. | $118.10 | 2025 | Symplicity G3 |
| Pfizer INC. | $114.56 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.82 | 2019-2025 | Ofev, Jascayd |
| Novartis Pharmaceuticals Corporation | $84.96 | 2019-2022 | |
| Abbvie INC. | $80.61 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $61.29 | 2019-2022 | |
| Dexcom, INC. | $52.13 | 2024 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $38.45 | 2022-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Sanofi-Aventis U.S. LLC | $28.71 | 2019 | |
| Ironwood Pharmaceuticals, INC | $18.18 | 2019 | |
| Amgen INC. | $17.30 | 2023 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $14.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nahid Elyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.